• Explore /
  • Poster
  • / Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Abstract Poster

Authors

null

Jianming Xu

Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China

Jianming Xu , Rongrui Liu , Yanqiao Zhang , Nong Xu , Qingxia Fan , Shegan Gao , Hongming Pan , Mingquan Cai , Dong Yan , Qianqian Liang , Qiong Wu , Baohong Guo , Yakun Qi , Ting Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03925870

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4062)

DOI

10.1200/JCO.2021.39.15_suppl.4062

Abstract #

4062

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Gang Jin

First Author: Jianqing Zhu

First Author: Wei Wang

First Author: Harry H. Yoon